Nanoporous silica microparticle interaction with toll-like receptor agonists in macrophages

被引:22
|
作者
Cejudo-Guillen, M. [1 ,2 ]
Ramiro-Gutierrez, M. L. [3 ]
Labrador-Garrido, A. [1 ,2 ]
Diaz-Cuenca, A. [3 ]
Pozo, D. [1 ,2 ,4 ]
机构
[1] CABIMER Andalusian Ctr Mol Biol & Regenerat Med C, E-41092 Seville, Spain
[2] Univ Seville Med Sch, Dept Med Biochem Mol Biol & Immunol, E-41009 Seville, Spain
[3] CSIC Univ Seville, Mat Sci Inst Seville ICMS, E-41092 Seville, Spain
[4] BIONAND Andalusian Ctr Nanomed & Biotechnol, E-29590 Malaga, Spain
关键词
Nanoporous silica microparticles; Macrophage; Innate immunity; Toll-like receptor; MESOPOROUS SILICA; DRUG-DELIVERY; INNATE IMMUNITY; IN-VITRO; NANOPARTICLES; CELLS; BIOCOMPATIBILITY; PARTICLES; FUNCTIONALIZATION; CYTOTOXICITY;
D O I
10.1016/j.actbio.2012.07.026
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Nanoporous silica microparticles (NSiO2-MP) are considered to be potential drug delivery systems and scaffolding platforms in tissue engineering. However, few biocompatibility studies regarding NSiO2-MP interaction with the immune system have been reported. Toll-like receptors (TLR) are involved in host defence as well as autoimmune and inflammatory diseases. The results show that NSiO2-MP up to 100 mu g ml(-1) do not affect macrophage cell viability after 24 h cell culture. Moreover, NSiO2-MP do not compromise the cell viability of TLR-activated Raw 264.7 cells, for either cell surface TLR (TLR1/TLR2/TLR4/TLR6) or endocytic compartment TLR (TLR3/TLR7/TLR9). Furthermore, Raw 264.7 cells do not respond to NSiO2-MP exposure in terms of IL-6 or IL-10 secretion. NSiO2-MP co-treatment in the presence of TLR ligands does not impair or enhance the secretion of the pro-inflammatory cytokine IL-6 or the regulatory cytokine IL-10. Thus, NSiO2-MP do not affect macrophage polarization towards a pro-inflammatory or immunosuppressive status, representing added value in terms of biocompatibility compared with other SiO2-based micro- and nanoparticles. (C) 2012 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:4295 / 4303
页数:9
相关论文
共 50 条
  • [1] Toll-like Receptor Agonists Promote Prolonged Triglyceride Storage in Macrophages
    Huang, Ying-ling
    Morales-Rosado, Joel
    Ray, Jessica
    Myers, Timothy G.
    Kho, Terry
    Lu, Mingfang
    Munford, Robert S.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (05) : 3001 - 3012
  • [2] Toll-like receptor agonists and cancer
    不详
    NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (07) : 511 - 511
  • [3] Radiotherapy and Toll-Like Receptor Agonists
    Marabelle, Aurelien
    Filatenkov, Alex
    Sagiv-Barfi, Idit
    Kohrt, Holbrook
    SEMINARS IN RADIATION ONCOLOGY, 2015, 25 (01) : 34 - 39
  • [4] Role of Nod2 in the response of macrophages to Toll-like receptor agonists
    Pauleau, AL
    Murray, PJ
    MOLECULAR AND CELLULAR BIOLOGY, 2003, 23 (21) : 7531 - 7539
  • [5] Toll-like receptor (TLR) agonists upregulate Notch receptors in murine macrophages
    Palaga, Tanapat
    JOURNAL OF IMMUNOLOGY, 2006, 176 : S194 - S194
  • [6] Role of Nod2 in the response of macrophages to toll-like receptor agonists
    Desreumaux, P
    Malapel, M
    GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 2003, 28 (03): : 319 - 320
  • [7] Toll-like receptor 7 agonists and skin
    Novak, Natalija
    Yu, Chun-Feng
    Bieber, Thomas
    Allam, Jean-Pierre
    DRUG NEWS & PERSPECTIVES, 2008, 21 (03) : 158 - 165
  • [8] Toll-Like Receptor Agonists Are They Good Adjuvants?
    Gnjatic, Sacha
    Sawhney, Nikhil B.
    Bhardwaj, Nina
    CANCER JOURNAL, 2010, 16 (04): : 382 - 391
  • [9] Toll-like receptor agonists in cancer therapy
    Adams, Sylvia
    IMMUNOTHERAPY, 2009, 1 (06) : 949 - 964
  • [10] Clinical investigations of Toll-like receptor agonists
    Meyer, Thomas
    Stockfleth, Eggert
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (07) : 1051 - 1065